The clinical information you need, at your fingertips.

Medical News for You

Ann Intern Med

38m

Supervised rehab boosts recovery after ACL surgery

Four months of supervised exercise and education improved pain, function, and knee satisfaction in young adults with persistent symptoms. . .

EADV 2026

Oral therapy improves vitiligo repigmentation in phase 3 trials

Litfulo (ritlecitinib), already approved for severe alopecia areata, is being tested for an additional autoimmune skin condition. . .

FDA

Ibogaine: FDA seeks to speed psychedelics research

Ibogaine now has federal momentum, and how its early trials are designed may show where the development of psychedelics is headed. . .

Radiology

Minimally invasive procedure may offer lasting carpal tunnel relief

A steroid-free, ultrasound-guided procedure produced sustained improvements through 6 months in patients with refractory carpal tunnel syndrome. . .

EClinicalMedicine

GLP-1 drugs stand out for stroke risk reduction in diabetes

Nationwide data linked GLP-1 receptor agonists—but not SGLT2 or DPP-4 inhibitors—to lower ischemic stroke risk in type 2 diabetes. . .

FDA

FDA expands Jaypirca to first-line treatment of CLL/SLL

The first approved non-covalent BTK inhibitor can now be used as initial therapy in adults without a known 17p deletion. . .

Nat Metab

10h

UPFs spike insulin, even with matched nutrients

Industrial food processing seems to change how the body handles a meal, even when nutrients are held equal. . .

Company news

13h

Semaglutide linked to lower liver fat in adults with obesity

In a small exploratory analysis, 23 of 26 participants with elevated liver fat reached normal levels after 72 weeks. . .

Ann Intern Med

Nearly a third of new advanced practice nurses are for-profit grads

The share has risen from about one in forty at the start of the 2010s in the four states studied, but the level varies widely from state to state. . .

Ann Intern Med

ACP recommends hormone therapy first for menopausal hot flashes

New guidance lays out a treatment hierarchy for vasomotor symptoms, with SNRIs second-line and newer neurokinin receptor antagonists among third-line options. . .